Stryker to Invest $400 Million in CMR Surgical, Gets Option
Stryker will invest about $400 million in Britain’s CMR Surgical and become its sole U.S. sales agent, with an option to buy the company.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reports that Stryker has agreed to invest about $400 million in British company CMR Surgical. The transaction includes an exclusive option to purchase all of CMR Surgical’s outstanding equity. Stryker will also become the company’s sole commercial sales agent in the U.S. for its Versius robotic-surgery portfolio.
Versius is designed for a range of soft-tissue procedures, while CMR Surgical will remain responsible for developing the portfolio outside the U.S. Stryker already operates in orthopedic robotic surgery through its Mako platform. The company said the agreement expands on its expertise in endoscopy, visualization and other surgical technologies as demand for robot-assisted procedures grows.
The companies did not disclose the size of Stryker’s initial stake or the financial terms of a possible full acquisition. Under the option, Stryker could eventually buy 100% of CMR Surgical’s outstanding equity, subject to the agreement’s conditions.
why it matters
The agreement broadens Stryker’s exposure to surgical robotics and gives it a potential route to full ownership of CMR Surgical. Terms for any future takeover remain undisclosed.
instruments
sources
- Stryker to Invest $400 Million in CMR Surgical, Gets Option to Buy Company — Dow Jones Newswires, 12 October 2026 at 12:43 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗